We conducted a retrospective evaluation of response and survival for 293 patients with multiple myeloma treated since June 2000 with primary thalidomide-or bortezomib-based combinations, of whom 207 patients received intensive therapy supported by autologous blood stem cells within the first year. Survival times were calculated after a landmark of 1 year from start of therapy, so that subsequent median survival was 8.9 years for patients with CR, 4.9 years for those with PR and 0.6 year for patients with NR (Po0.001). Multivariate analyses confirmed CR or PR as the major favorable factors with less impact on prognosis for age or disease stage. Both novel agents and high-dose therapy (HDT) resulted in high frequencies of PR or CR, with early HDT useful for many patients with NR or PR in improving response status and subsequent survival.
INTRODUCTION
Major advances in treatment have improved the outcome of patients with multiple myeloma. New agents and their combinations, along with more frequent use of intensive therapy, have induced more frequent remissions and have prolonged survival in comparison with standard therapies. [1] [2] [3] [4] [5] [6] [7] [8] Our recent analysis showed the major impact of CR and PR on survival and the independent roles of tumor stage and early intensive therapy (high-dose therapy (HDT)) on lifespan. 9 This report updated these findings, included patients of all ages, but limited the analysis to patients treated with recent novel therapies. We also attempted to identify patients more likely to benefit from early intensive treatment.
PATIENTS AND METHODS
We evaluated outcomes of 293 consecutive, newly diagnosed patients with multiple myeloma treated between 2000 and 2012. The median age was 60, median Hgb was 10.9 g/dL, 11% showed corrected serum calcium 411 mg/dL and 11% had serum creatinine 42 mg/dL; frequencies of disease stages 1, 2 or 3 were 38%, 33% and 29%, respectively. 10 All received initial treatment with intermittent, high-dose dexamethasone either with thalidomide (TD for 128 patients, [2000] [2001] [2002] [2003] , or with bortezomib and thalidomide or lenalidomide (VTD or VRD for 165 patients, 2003-2012) in sequential protocols. 3, 7, 8 Within the first year, 207 patients (71%) received high-dose, melphalan-based intensive therapy supported by autologous stem cells (HDT) in sequential protocols described previously. 11, 12 All patients in CR were followed without maintenance; all patients in PR received thalidomide or lenalidomide alone as maintenance until relapse; upon relapse, resumption of a proteasome-inhibitor combination was given to most patients with varying effectiveness. Unlike our previous analysis, patients of all ages were included, including 85 patients older than 65. Only patients who met international criteria for measurable disease were included (serum myeloma protein X1.0 g/ 100 mL, Bence-Jones protein X200 mg/day, free light chains X10 mg/dL provided ratio was abnormal); 13 patients with lower myeloma protein or nonsecretory disease were excluded. For patients older or younger than 65, the frequencies and severity of anemia, renal failure, elevated B 2 M and distribution of tumor stage, were virtually identical.
Intensive therapy (HDT)
HDT was given after a median 4.4 months (range 2-11.8 months). For correlations of response with survival, patients who received the different primary and/or intensive therapies were combined in the analyses. Those patients who were not intensified either refused such treatment, were unable to satisfy social or geographic requirements, or were denied insurance coverage. Among patients older than 65, 45% received HDT in comparison with 81% of younger patients (Po0.01). Written permission for this retrospective review was provided by our Institutional Review Board, in accordance with an assurance approved by the Department of Health and Human Services.
Clinical response
Applying the EBMT (European Group for Blood and Marrow Transplantation) criteria, PR was defined by reduction of serum myeloma protein by 450%, Bence-Jones protein by 490% and marrow plasmacytosis to o10%; CR required disappearance of myeloma protein by immunofixation for at least 2 months.
14 Frequencies of response within 1 year were higher for patients who received bortezomib-vs thalidomide-based combinations (90 vs 76%, Po0.01).
Statistical methods
All patients were assessed for pretreatment stage, response to primary and intensive therapies, and survival. Deaths have occurred in 173 patients (59%), and median follow up of 120 living patients was 6.6 years. Survival was calculated using the Kaplan-Meier method and differences compared using the log-rank test. 15, 16 Because PR or CR occurred within 12 months in all but two patients, landmark analysis was used to compare survival among the response groups defined at 12 months. 17 Conforming with landmark analysis, survival was censored for one patient with PR and later conversion to CR (12.6 months), for one patient with NR and later conversion to PR (13.9 months) and for three patients with primary CR and later HDT (12.1, 19.3 and 32.5 months). Cox proportional hazard regression models were fitted for multivariate analysis. 18 All 21 patients who died within 12 months were excluded, consisting of 9 patients with NR, 7 patients 465, and 18 patients who did not receive HDT.
RESULTS

Survival
Multiple factors were assessed for survival after landmark of 1 year, but only three major features were dominant by univariant analysis (Po0.01) (Figure 1 ). Most marked were the differences in survival based on response status (left panel); survival was significantly longer for those with CR as best outcome (median 8.9 years) than with PR (median 4.9 years) or with NR (median 0.6 year). Figure 2 shows significantly longer survival for 21 of 26 patients with NR that converted to PR after HDT (81%) (left panel) and for 48 of 151 patients with PR that converted to CR (32%) (middle panel). Among those with PR, conversion to CR after HDT was limited to patients with lower myeloma protein values (Table 1) .
After primary therapy, CR was defined in 37 patients. Among 27 patients who received early HDT, survival was longer than that observed in 10 similar patients who did not receive HDT, but the difference was NS (Figure 2 , right panel).
Complete remission Among 85 patients with CR, the remission duration was o2 years in 39 patients (46%) for whom the median survival from landmark of 12 months (4.4 years) was similar to that of patients with PR (median 4.9 years); for the remaining 46 patients with CR42 years, median survival was projected at B11 years (Po0.01).
Multivariate analysis
Cox proportional hazard models at landmark of 1 year were used to assess the effect of prognostic factors on survival. As summarized in Table 2 , CR, PR and HDT were the primary independent factors associated with significantly longer survival Survival in years after landmark of 1 year Figure 2 . Longer survival after a landmark of 1 year after HDT for patients with NR converted to PR with HDT, than for those with persistent NR or for those with primary NR without HDT (left panel). Longer survival after HDT for patients with PR converted to CR, than for those with persistent PR or for those with primary PR without HDT (middle panel). Slightly longer survival for patients with primary CR after added HDT than for those without added HDT (right panel).
(Po0.05). These features were dominant over other features, such as age or disease stage, where the impact on survival was less.
DISCUSSION
This report confirms previous findings on the major impact of CR or PR on survival, after including patients of all ages and limiting our analysis to those who received primary novel agent combinations since 2000. In comparison with our previous study, we observed higher frequencies of remission with both novel therapies and HDT. Calculations of survival after a landmark of 1 year, and the infrequency of censored data, contributed to the more marked differences in survival now observed for patients with NR, PR and CR in comparison with our previous report; 9 these results supported further the conclusion of Lahuerta et al. 19 and of Gertz et al. 20 on the importance of CR and PR on survival. Persistent NR was the most immediate and ominous problem that prevailed in only 10% of patients treated with recent programs, whose survival remained short and similar to that described by Snapper 50 years ago for patients unable to receive effective therapy. 21 Multivariate analyses confirmed the primacy of PR and CR, but the absence of cytogenetic studies remained a shortcoming.
Thus, in addition to the novel therapies, HDT provided a major vehicle for increasing the frequencies of PR and CR among those with initial NR and PR. The role of HDT for patients in CR after primary therapy has been controversial for many years, especially as the frequency of primary CR has been low and a controlled study difficult. Although we observed a longer survival for those in primary CR who received HDT, in comparison with those who did not, the difference was NS, probably because the number of patients was low and the follow-up short. However, multivariate analysis showed a positive and independent contribution of HDT to survival even without a meaningful change in response status. Thus, unless contradicting data become available, HDT should be offered to all patients with CR after primary therapy who qualify by medical criteria. Yet, the occurrence of CR was not associated with long survival unless durations of CR were sustained for at least 2 years, similar to the findings of Barlogie et al. 22 More sensitive phenotypic or molecular studies of residual disease may identify those patients in CR who are more likely to have short remission and survival times and for whom further investigational therapies should be considered.
These findings provide a rational perspective for the selection of patients for HDT after primary therapy with current novel agents. Primary resistant disease has become uncommon but, when it occurs, should be considered for prompt HDT in order to prevent complications and provide a high likelihood of PR with longer survival. HDT converted disease status from PR to CR in nearly one-third of treated patients, but primarily in those with low myeloma protein levels; patients with these features should receive early HDT regardless of age and/or minor medical problems. Multivariate analysis also showed independent benefit from HDT even without a major change in response status, perhaps because of modest reductions of myeloma cell number in many patients. 23 Whether HDT benefits specific subgroups, such as those with 'harmful' cytogenetic features or patients in CR by immunofixation but without residual clonal cells on phenotypic or molecular analysis, requires further study. On the basis of current evidence and provided patients meet medical criteria, all patients should be considered for early HDT soon after diagnosis. Thus, recent improvements in survival can be attributed primarily to the higher frequencies of PR and CR with modern therapies, that include novel drug combinations and more frequent intensive therapy. Recognition of patients with apparent CR by immunofixation, but with residual clonal cells by special studies, may identify those who may benefit from further treatments. Intensive therapy for multiple myeloma R Alexanian et al
